EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program

Vipul Jairath iD, David T Rubin, Bram Verstockt iD, Ayhan H Çekin, Maria T Abreu iD, Charlie W Lees, Marc Fellmann iD, John C Woolcott, Catherine Crosby, Joseph Wu, Abhishek Bhattacharjee, David Herman und 2 weitere

Inflammatory Bowel Diseases · 10.04.2025 · 31 (4) · 923-934

DOI: 10.1093/ibd/izae111 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 20.06.2024. Verfasst von Vipul Jairath und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Feces, C-Reactive Protein, Colitis, Ulcerative. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biomarkers offer potential alternatives to endoscopies in monitoring ulcerative colitis (UC) progression and therapeutic response. This post hoc analysis of the ELEVATE UC clinical program assessed potential predictive values of fecal calprotectin (fCAL) and high-sensitivity C-reactive protein (hsCRP) as biomarkers and associated responses to etrasimod, an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC, in 2 phase 3 clinical trials.

Methods

In ELEVATE UC 52 and ELEVATE UC 12, patients were randomized 2:1 to 2 mg of etrasimod once daily or placebo for 52 or 12 weeks, respectively. Fecal calprotectin/hsCRP differences between responders and nonresponders for efficacy end points (clinical remission, clinical response, endoscopic improvement-histologic remission [EIHR]) were assessed by Wilcoxon P-values. Sensitivity and specificity were presented as receiver operating characteristics (ROC) curves with area under the curve (AUC).

Results

In ELEVATE UC 52 and ELEVATE UC 12, 289 and 238 patients received etrasimod and 144 and 116 received placebo, respectively. Baseline fCAL/hsCRP concentrations were generally balanced. Both trials had lower week-12 median fCAL levels in week-12 responders vs nonresponders receiving etrasimod for clinical remission, clinical response, and EIHR (all P < .001), with similar trends for hsCRP levels (all P < .01). For etrasimod, AUCs for fCAL/hsCRP and EIHR were 0.85/0.74 (week 12; ELEVATE UC 52), 0.83/0.69 (week 52; ELEVATE UC 52), and 0.80/0.65 (week 12; ELEVATE UC 12).

Conclusions

Fecal calprotectin/hsCRP levels decreased with etrasimod treatment; ROC analyses indicated a prognostic correlation between fCAL changes during induction and short-/long-term treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte L1 Antigen ComplexFecesC-Reactive ProteinColitis, UlcerativeHumansMaleFemaleMiddle AgedBiomarkersAdultDouble-Blind MethodPrognosisROC CurveAgedFollow-Up Studies

Stichwörter der Autor:innen

biomarkeretrasimodphase 3 clinical trialsphingosine 1-phosphateulcerative colitis

Substanzen

Leukocyte L1 Antigen ComplexC-Reactive ProteinBiomarkers

Autor:innen und Institutionen

  • Department of Medicine and Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
  • University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
  • Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Department of Chronic Diseases and Metabolism, Translational Research in Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.
  • Department of Gastroenterology, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey.
  • Division of Gastroenterology, Crohn's and Colitis Center, University of Miami Miller School of Medicine, Miami, FL, USA.

ORCID-Profile: Vipul Jairath, Bram Verstockt, Maria T Abreu, Marc Fellmann, Britta Siegmund

Förderung

  • Pfizer

Zitieren

APA

Jairath, V., Rubin, D. T., Verstockt, B., Çekin, A. H., Abreu, M. T., Lees, C. W., Fellmann, M., Woolcott, J. C., Crosby, C., Wu, J., Bhattacharjee, A., Herman, D., Gu, G., & Siegmund, B. (2025). The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases, 31(4), 923-934. https://doi.org/10.1093/ibd/izae111

Vancouver

Jairath V, Rubin DT, Verstockt B, Çekin AH, Abreu MT, Lees CW, et al. The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 2025;31(4):923-934. doi:10.1093/ibd/izae111

BibTeX
@article{Jairath2025,
  author = {Jairath, Vipul and Rubin, David T and Verstockt, Bram and Çekin, Ayhan H and Abreu, Maria T and Lees, Charlie W and Fellmann, Marc and Woolcott, John C and Crosby, Catherine and Wu, Joseph and Bhattacharjee, Abhishek and Herman, David and Gu, Guibao and Siegmund, Britta},
  title = {The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {4},
  pages = {923--934},
  doi = {10.1093/ibd/izae111}
}
Kostenlos starten →